{"id":"cetirizine-drops","safety":{"commonSideEffects":[{"rate":"2-3%","effect":"Headache"},{"rate":"1-2%","effect":"Somnolence"},{"rate":"1-2%","effect":"Fatigue"},{"rate":"1-2%","effect":"Dry mouth"},{"rate":"1-2%","effect":"Pharyngitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cetirizine competitively inhibits histamine at the H1 receptor, reducing the release and effects of inflammatory mediators responsible for allergic symptoms. As a second-generation antihistamine, it is highly selective for H1 receptors and does not significantly cross the blood-brain barrier, resulting in minimal sedation compared to first-generation antihistamines.","oneSentence":"Cetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on mast cells and basophils, preventing allergic cascade activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:56.912Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis (seasonal and perennial)"},{"name":"Chronic urticaria"},{"name":"Allergic conjunctivitis"},{"name":"Allergic asthma (adjunctive)"}]},"trialDetails":[{"nctId":"NCT00291642","phase":"PHASE2","title":"A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-01-01","conditions":"Rhinitis, Allergic, Seasonal","enrollment":551},{"nctId":"NCT01881113","phase":"PHASE3","title":"A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2013-06","conditions":"Allergic Conjunctivitis","enrollment":101},{"nctId":"NCT01551056","phase":"PHASE3","title":"A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2012-03","conditions":"Allergic Conjunctivitis","enrollment":91},{"nctId":"NCT01685242","phase":"PHASE3","title":"A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2012-09","conditions":"Allergic Conjunctivitis","enrollment":100},{"nctId":"NCT02173249","phase":"PHASE1","title":"A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2014-06","conditions":"Healthy","enrollment":11},{"nctId":"NCT01134328","phase":"PHASE2","title":"Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2010-05","conditions":"Allergic Conjunctivitis","enrollment":83},{"nctId":"NCT01495338","phase":"PHASE1","title":"A Comparison of the Safety and Comfort of AC-170","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2011-12","conditions":"Normal Ocular Health","enrollment":60},{"nctId":"NCT02756624","phase":"PHASE3","title":"A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2016-04","conditions":"Healthy Subjects","enrollment":516},{"nctId":"NCT02132169","phase":"PHASE3","title":"A Multi-Center Study Evaluating the Safety of AC-170 0.24%","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2014-05","conditions":"Atopic Disease (Including Allergic Conjunctivitis)","enrollment":512},{"nctId":"NCT01332188","phase":"PHASE2, PHASE3","title":"Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2011-04","conditions":"Allergic Conjunctivitis","enrollment":101}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zyrtec","Simulant of Diphenhydramine Hydrochloride Injection"],"phase":"marketed","status":"active","brandName":"Cetirizine drops","genericName":"Cetirizine drops","companyName":"UCB Pharma","companyId":"ucb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on mast cells and basophils, preventing allergic cascade activation. Used for Allergic rhinitis (seasonal and perennial), Chronic urticaria, Allergic conjunctivitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}